AirSculpt Q3 revenue falls 8.7% to $31.9 million
Por Heidi Cuthbert Pontos principais
- AirSculpt Technologies (NASDAQ:AIRS) reported third-quarter 2026 revenue of $31.9 million, down 8.7% year over year, as procedure volumes declined.
- Net loss narrowed to $7.173 million from $9.512 million, but adjusted EBITDA fell to $393,000 from $3.039 million.
- AirSculpt reduced its 2026 revenue forecast to $144 million–$146 million and adjusted EBITDA guidance to $9 million–$10 million, while completing a $39 million debt refinancing.
AirSculpt Technologies (NASDAQ:AIRS) reported third-quarter 2026 revenue of $31.9 million, down 8.7% year over year, and lowered its full-year financial outlook following weaker demand for its body contouring procedures.
Revenue declined as same-center procedure volumes fell 9.6%, while nine-month revenue decreased 3.5% to $114.2 million, reflecting continued pressure on patient demand.
The company's net loss narrowed to $7.173 million from $9.512 million in the prior-year quarter, although adjusted EBITDA, a non-GAAP earnings measure, dropped to $393,000 from $3.039 million.
AirSculpt now expects full-year 2026 revenue of approximately $144 million–$146 million and adjusted EBITDA of $9 million–$10 million, below its previous forecasts, while September-end cash stood at $15.182 million and quarterly operating cash outflow reached $3.475 million.
On November 5, AirSculpt completed a refinancing that provided a $39 million funded senior secured term loan and an undrawn revolving credit facility of up to $5 million, both maturing November 5, 2031.
AirSculpt provides minimally invasive body contouring procedures through its proprietary AirSculpt technology, operating specialised treatment centres across the United States and Canada.SEO and publishing metadata
